Cg Oncology (CGON) | Stock Overview & Key Data

Cg Oncology, Inc. | Healthcare

$26.56

6.84%

| Cg Oncology Stock Comparison:

Cg Oncology vs Vertex Cg Oncology vs Regeneron Cg Oncology vs Amicus Therapeutics Cg Oncology vs Kymera Therapeutics Cg Oncology vs Tarsus Cg Oncology vs S&P 500 | Market

Cg Oncology Performance Comparison

Loading chart data...

Cg Oncology

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $24.67 High: $27.25

on May 20, 2025

52 Week Range

Low: $14.80 High: $40.47

on April 9, 2025

on November 11, 2024

All-Time High: $50.23 on February 12, 2024

Key Statistics

Market Cap i $2.0B

EPS i -1.50

P/E Ratio (TTM) i -18.60

Forward P/E i -14.73

P/B Ratio i 2.84

PEG Ratio i -14.73

Div. Yield i 0.00%

ROE i -16.58%

Beta i N/A

Debt to Equity i 0.15

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i -81,161.54%

Profit Margin i 0.00%

Returns and Earnings

Return on Assets (TTM) i -12.85%

Return on Equity (TTM) i -16.58%

EBITDA i $-134.3M

Net Income (TTM) i $-105.6M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Cg Oncology CGON	2.00B Small-cap	9.84%	30.13%	-5.88%	-17.62%	-8.32%	-18.53%	-23.92%	-23.92%
Vertex VRTX	114.83B Large-cap	3.50%	-6.37%	-6.92%	-0.91%	10.19%	-2.16%	63.33%	55.25%
Regeneron REGN	65.09B Large-cap	7.03%	9.44%	-11.71%	-17.33%	-14.08%	-37.60%	-11.28%	0.30%
Amicus Therapeutics FOLD	1.93B Small-cap	9.63%	-1.64%	-27.23%	-31.18%	-29.11%	-31.68%	-16.98%	-47.12%
Kymera Therapeutics KYMR	2.00B Small-cap	0.90%	15.68%	-16.03%	-28.67%	-23.16%	-7.75%	108.70%	-5.56%
Tarsus TARS	1.89B Small-cap	8.15%	-7.57%	-7.96%	-3.74%	-18.69%	28.19%	212.53%	118.08%

Ownership & Short Interest

Insider Ownership i 1.17%

Institutional Ownership i 104.40%

Shares Short i 11M

Short Ratio i 5.94

Short % of Shares Outstanding i 15.59%

Average 10-Day Volume i 1M

Average 90-Day Volume i 2M

Cg Oncology Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Cg Oncology would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is CGON's 52-week high and low?

In the last 52 weeks, Cg Oncology reached a high of $40.47 (on November 11, 2024) and a low of $14.80 (on April 9, 2025).

What is the market cap and P/E ratio for CGON?

Curious about Cg Oncology's size and valuation? Its market capitalization stands at 2.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is -18.60, and the forward P/E (looking ahead) is -14.73.

Does CGON pay dividends? If so, what's the yield?

As for dividends, Cg Oncology isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Cg Oncology's main competitors or similar companies to consider before investing?

When looking at Cg Oncology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.83B	Healthcare	Biotechnology	-2.16%	63.33%
Regeneron REGN	65.09B	Healthcare	Biotechnology	-37.60%	-11.28%
Amicus Therapeutics FOLD	1.93B	Healthcare	Biotechnology	-31.68%	-16.98%
Kymera Therapeutics KYMR	2.00B	Healthcare	Biotechnology	-7.75%	108.70%
Tarsus TARS	1.89B	Healthcare	Biotechnology	28.19%	212.53%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Cg Oncology, Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Cg Oncology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -16.58%, the Debt to Equity ratio from the most recent quarter is 0.15, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for CGON?

Looking at Cg Oncology's growth, its revenue over the trailing twelve months (TTM) was $662K. Compared to the same quarter last year (YoY), quarterly revenue grew by -90.20%, and quarterly earnings saw a YoY growth of -90.17%.

How much of CGON stock is held by insiders and institutions?

Wondering who owns Cg Oncology stock? Company insiders (like executives and directors) hold about 1.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 104.40%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.